On September 28, 2021 Genelux entered into an exclusive rights agreement with Newsoara Biopharma Co., Ltd for Olvi-Vec and the Genelux oncolytic virus library in the Greater China Region. Newsoara is a clinical-stage biopharmaceutical company with the mission to develop and commercialize life changing medicines for the treatment of patients with cancer, autoimmune, metabolic and other major diseases in China and around the world. READ RELEASE



V2ACT – Joint Venture
In January 2019, V2ACT Therapeutics, LLC was formed as a joint venture between Genelux Corporation and TVAX Biomedical, Inc. to develop and test V2ACT Immunotherapy, a novel immunotherapy modality.


V2ACT Therapeutics was formed to clinically explore compelling scientific evidence that combining oncolytic virotherapy and adoptive cell therapy can safely achieve superior efficacies for the treatment of pancreatic and other solid tumor cancers: vaccination increases the numbers of neoantigen-specific T cells in the body and Olvi-Vec kills cancer cells and potentiates T cells by increasing cancer tissue receptivity to subsequently-administered adoptively transferred neoantigen-specific effector T cells. READ RELEASE



ELIAS Animal Health
On November 21, 2021, Genelux entered into an exclusive worldwide licensing agreement for V-VET1, its clinical stage animal health product candidate, with ELIAS Animal Health.


ELIAS is a biotechnology company working to advance its novel T cell-based immunotherapies for the treatment of cancer in veterinary medicine. V-VET1 is a vaccinia viral strain which selectively replicates in cancer cells causing cell death (apoptosis). READ RELEASE

Partner with us


As an innovative drug developer, we are committed to establishing mutually-beneficial, long-term partnerships, grounded in trust and transparency, to develop cutting edge science and differentiated pharmaceutical products to deliver transformational benefits to patients and the healthcare system.